Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Clinical and experimental studies of a novel P525R FUS mutation in amyotrophic lateral sclerosis.

Kuang L, Kamelgarn M, Arenas A, Gal J, Taylor D, Gong W, Brown M, St Clair D, Kasarskis EJ, Zhu H.

Neurol Genet. 2017 Jul 20;3(4):e172. doi: 10.1212/NXG.0000000000000172. eCollection 2017 Aug.

2.

Purpose in Life in ALS Patient-Caregiver Dyads: A Multilevel Longitudinal Analysis.

Garcia NE, Morey JN, Kasarskis EJ, Segerstrom SC.

Health Psychol. 2017 May 25. doi: 10.1037/hea0000507. [Epub ahead of print]

PMID:
28541074
3.

What lurks in the mind of someone with dysphagia?

Kasarskis EJ.

Muscle Nerve. 2017 Jul;56(1):2-3. doi: 10.1002/mus.25683. Epub 2017 Jun 5. No abstract available.

PMID:
28472864
4.

Fixed dynamometry is more sensitive than vital capacity or ALS rating scale.

Andres PL, Allred MP, Stephens HE, Proffitt Bunnell M, Siener C, Macklin EA, Haines T, English RA, Fetterman KA, Kasarskis EJ, Florence J, Simmons Z, Cudkowicz ME.

Muscle Nerve. 2017 Jan 24. doi: 10.1002/mus.25586. [Epub ahead of print]

PMID:
28120413
5.

ALS mutant SOD1 interacts with G3BP1 and affects stress granule dynamics.

Gal J, Kuang L, Barnett KR, Zhu BZ, Shissler SC, Korotkov KV, Hayward LJ, Kasarskis EJ, Zhu H.

Acta Neuropathol. 2016 Oct;132(4):563-76. doi: 10.1007/s00401-016-1601-x. Epub 2016 Aug 1.

6.

Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.

Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS.

Neurology. 2016 Mar 1;86(9):813-20. doi: 10.1212/WNL.0000000000002305. Epub 2016 Jan 22.

7.

Relationship of creatine kinase to body composition, disease state, and longevity in ALS.

Gibson SB, Kasarskis EJ, Hu N, Pulst SM, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Kryscio RJ, Bromberg MB.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):473-7. doi: 10.3109/21678421.2015.1062516. Epub 2015 Aug 27.

8.

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun.

9.

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24.

10.

Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromberg MB, Kryscio RJ; ALS Nutrition/NIPPV Study Group.

Am J Clin Nutr. 2014 Apr;99(4):792-803. doi: 10.3945/ajcn.113.069997. Epub 2014 Feb 12.

11.

FUsed in sarcoma is a novel regulator of manganese superoxide dismutase gene transcription.

Dhar SK, Zhang J, Gal J, Xu Y, Miao L, Lynn BC, Zhu H, Kasarskis EJ, St Clair DK.

Antioxid Redox Signal. 2014 Apr 1;20(10):1550-66. doi: 10.1089/ars.2012.4984. Epub 2013 Sep 20.

12.

Expressive disclosure to improve well-being in patients with amyotrophic lateral sclerosis: a randomised, controlled trial.

Averill AJ, Kasarskis EJ, Segerstrom SC.

Psychol Health. 2013;28(6):701-13. doi: 10.1080/08870446.2012.754891. Epub 2013 Jan 7.

13.

Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.

Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA; Neals/Cytokinetics Study Team.

Amyotroph Lateral Scler. 2012 Sep;13(5):430-8. doi: 10.3109/17482968.2012.684214. Epub 2012 May 16.

PMID:
22591195
14.

Unilateral parotid electron beam radiotherapy as palliative treatment for sialorrhea in amyotrophic lateral sclerosis.

Kasarskis EJ, Hodskins J, St Clair WH.

J Neurol Sci. 2011 Sep 15;308(1-2):155-7. doi: 10.1016/j.jns.2011.06.016. Epub 2011 Jul 2.

PMID:
21726879
15.

What does body mass index measure in amyotrophic lateral sclerosis and why should we care?

Kasarskis EJ.

Muscle Nerve. 2011 Jul;44(1):4-5. doi: 10.1002/mus.22113. Epub 2011 May 23. No abstract available.

PMID:
21607986
16.

The ALS Nutrition/NIPPV Study: design, feasibility, and initial results.

Kasarskis EJ, Mendiondo MS, Wells S, Malguizo MS, Thompson M, Healey M, Kryscio RJ; ALS Nutrition/NIPPV Study Group.

Amyotroph Lateral Scler. 2011 Jan;12(1):17-25. doi: 10.3109/17482968.2010.515225.

PMID:
21271789
17.

Neurological mortality among Gulf War veterans.

Horner RD, Feussner JR, Kasarskis EJ.

Am J Ind Med. 2010 May;53(5):548-9. doi: 10.1002/ajim.20809. No abstract available.

PMID:
20191602
18.

Web-based data management for a phase II clinical trial in ALS.

Buchsbaum R, Kaufmann P, Barsdorf AI, Arbing R, Montes J, Thompson JL; QALS Study Group.

Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):374-7. doi: 10.3109/17482960802378998.

PMID:
19922127
19.

Factors associated with survival in the National Registry of Veterans with ALS.

Pastula DM, Coffman CJ, Allen KD, Oddone EZ, Kasarskis EJ, Lindquist JH, Morgenlander JC, Norman BB, Rozear MP, Sams LA, Sabet A, Bedlack RS.

Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):332-8. doi: 10.3109/17482960802320545.

PMID:
19922120
20.

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2009 Oct 13;73(15):1227-33. doi: 10.1212/WNL.0b013e3181bc01a4. Review.

Supplemental Content

Loading ...
Support Center